223 related articles for article (PubMed ID: 19370640)
21. Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.
Police RL; Trask PC; Wang J; Olivares R; Khan S; Abbe A; Colosia A; Njue A; Sherril B; Ruiz-Soto R; Kaye JA; Hamadani M
J Oncol Pharm Pract; 2016 Oct; 22(5):666-78. PubMed ID: 26320127
[TBL] [Abstract][Full Text] [Related]
22. Rituximab maintenance therapy: a step forward in follicular lymphoma.
van Oers MH
Haematologica; 2007 Jun; 92(6):826-33. PubMed ID: 17550856
[TBL] [Abstract][Full Text] [Related]
23. Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data.
Andemariam B; Leonard JP
Clin Lymphoma Myeloma; 2006 Oct; 7 Suppl 1():S20-3. PubMed ID: 17101069
[TBL] [Abstract][Full Text] [Related]
24. Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.
Zhou X; Ma T; Zhang Y; Zhou N; Li J
PLoS One; 2017; 12(3):e0174648. PubMed ID: 28355276
[TBL] [Abstract][Full Text] [Related]
25. Rituximab for the treatment of follicular lymphoma.
Cheah CY; Lingaratnam S; Seymour JF
Future Oncol; 2013 Sep; 9(9):1283-98. PubMed ID: 23980675
[TBL] [Abstract][Full Text] [Related]
26. Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
Roy R; Gordon LI
J Natl Compr Canc Netw; 2011 May; 9(5):563-71. PubMed ID: 21550969
[TBL] [Abstract][Full Text] [Related]
27. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
[TBL] [Abstract][Full Text] [Related]
28. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
29. Rituximab maintenance in indolent lymphoma: indications and controversies.
van Oers MH
Curr Oncol Rep; 2007 Sep; 9(5):378-83. PubMed ID: 17706166
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
31. Principles of maintenance therapy.
Berinstein NL
Leuk Res; 2006 Mar; 30 Suppl 1():S3-10. PubMed ID: 16750676
[TBL] [Abstract][Full Text] [Related]
32. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.
Deconinck E; Miadi-Fargier H; Pen CL; Brice P
Pharmacoeconomics; 2010; 28(1):35-46. PubMed ID: 20014875
[TBL] [Abstract][Full Text] [Related]
34. Maintenance therapy in follicular lymphoma.
Michallet AS; Coiffier B; Salles G
Curr Opin Oncol; 2011 Sep; 23(5):449-54. PubMed ID: 21734580
[TBL] [Abstract][Full Text] [Related]
35. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
36. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.
Al Khabori M; de Almeida JR; Guyatt GH; Kuruvilla J; Crump M
J Natl Cancer Inst; 2012 Jan; 104(1):18-28. PubMed ID: 22190633
[TBL] [Abstract][Full Text] [Related]
37. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
38. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.
Nabhan C; Ollberding NJ; Villines D; Chiu BC; Caces DB; Valdez TV; Ghielmini M; Hsu Schmitz SF; Smith SM
Leuk Lymphoma; 2014 Jun; 55(6):1288-94. PubMed ID: 23998254
[TBL] [Abstract][Full Text] [Related]
39. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
[TBL] [Abstract][Full Text] [Related]
40. Rituximab maintenance therapy in follicular lymphoma comes of age.
Hiddemann W
Leuk Res; 2006 Mar; 30 Suppl 1():S1-2. PubMed ID: 16750672
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
